Efficacy and safety of upadacitinib through 140 weeks in adolescents and adults with moderate-to-severe atopic dermatitis: phase 3 randomized clinical trial results
Recommended Citation
Silverberg JI, Guttman-Yassky E, Simpson EL, Papp KA, Blauvelt A, Chu C, Chih-ho Hong H, Stein Gold LF, Bieber T, Kabashima K, Rosmarin D, Gamelli A, Calimlim B, Vigna N, Hu X, Yang Y, Wu X, Huang X, Suravaram S, Teixeira HD, Raymundo E, Irvine AD. Efficacy and safety of upadacitinib through 140 weeks in adolescents and adults with moderate-to-severe atopic dermatitis: phase 3 randomized clinical trial results. Br J Dermatol 2024; 190:II8.
Document Type
Conference Proceeding
Publication Date
2-7-2024
Publication Title
Br J Dermatol
Volume
190
First Page
II8
